LAS VEGAS – Dr. Rowland Illing, chief medical officer at Amazon Web Services (AWS), sat down with MobiHealthNews at the recent 2026 HIMSS Global Health Conference & Exposition here to discuss how AI and quantum computing could unlock new capabilities in healthcare, enabling organizations to solve complex problems and innovate in ways previously unimaginable. MobiHealthNews: Can you tell the readers about your job at Amazon Web Services? Dr. Rowland Illing: I'm the chief medical officer of Amazon

RESEARCH TRIANGLE PARK, N.C., April 03, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 12 newly-hired employees stock options to purchase an aggregate of 33,950 shares, and restricted stock units (RSUs) covering an aggregate of 123,350 shares, of BioCryst common stock. The options and RSUs were granted as of April 1, 2026, as inducements material to each employee entering into emplo

BEIJING, April 3, 2026 /PRNewswire/ -- Syneron Bio, a leader in intelligent platform-driven macrocyclic peptide drug discovery, announced the successful closing of its Series B financing on March 31th. The round was led by an international life-science fund, with co-lead participation from Decheng Capital, and CDH VGC. Additional investors included a wholly owned subsidiary of the Abu Dhabi Investment Authority ("ADIA"), True Light Capital, — an independent, wholly-owned subsidiary of Temasek, Q

Catheter Precision, a U.S.-based medical device company that formerly focused on bringing new solutions to market to improve the treatment of cardiac arrhythmias, has announced plans to end its cardiac electrophysiology business and focus on aviation. At the end of 2025, Catheter Precision acquired Flyte, a small, regional airline company that operates short-haul flights. Now, the company seems to be putting all of its eggs in the aviation basket. CEO: Cardiac assets better suited for larger com

Eyeing further development of its personalised cancer vaccine, Transgene on Friday signed a licensing agreement to access AI tech from its long-time partner, NEC Bio. The candidate, TG4050, is an individualised, MVA viral vector–based immunotherapy that incorporates tumour-specific neoantigens selected by NEC’s prediction platform, which uses machine learning to identify immunogenic mutations that are most likely to induce a strong immune response in each patient. With the selected neoantigens,

Gilead cuts staff in San MateoTakeda ends dementia partnership with DenaliGilead cuts staff in San MateoGilead Sciences is planning to let go of 51 staffers at its San Mateo, California location, according to a state Worker Adjustment and Retraining Notification (WARN) notice filed in late March. The headcount reduction, set to take effect on May 29, comes about a year after the biopharma eliminated 149 positions at its Foster City headquarters.A FirstWord analysis found that Gilead is the most

Syneron Bio said Friday it has closed its series B round, raising $150 million to further development of its AI-enabled macrocyclic peptide discovery platform, Synova. The Beijing-based biotech will also use the funds to advance its peptide pipeline into the clinic. "The completion of this financing further strengthens our cash position, enabling us to accelerate the development of multiple core pipeline programmes across oncology, autoimmune, metabolic, and rare diseases, with the goal of benef

The company is set to launch on an immediate basis MUMBAI, India and WARREN, N.J., April 3, 2026 /PRNewswire/ -- Cipla USA Inc. the wholly owned subsidiary of Cipla Limited(BSE: 500087) (NSE: CIPLA) (hereafter referred to as "Cipla") today announced final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Nintedanib Capsules, 100 mg and 150 mg, indicated for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Cipla's Nintedanib Capsu

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced plans to present at the upcoming 25 th Annual Needham Virtual Healthcare Conference. Pulse Biosciences’ Management is scheduled to present on Thursday, April 16, 2026, at 9:30 am ET. A live and recorded webcast of the presentation will be available on the “Events Calendar and Presentations” page of the compan

RESEARCH TRIANGLE PARK, N.C., April 03, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 12 newly-hired employees stock options to purchase an aggregate of 33,950 shares, and restricted stock units (RSUs) covering an aggregate of 123,350 shares, of BioCryst common stock. The options and RSUs were granted as of April 1, 2026, as inducements material to each employee entering into emp